US
Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
Application Note
A high-fidelity, modular platform for efficient multiplexed engineering of therapeutic hematopoietic stem and progenitor cells.
In this application note, we evaluate the Pin-point™ base editing platform as a tool for precise, safe and efficient engineering of hematopoietic stem and progenitor cells (HSPCs) by editing two therapeutically relevant targets known to reactivate expression of fetal hemoglobin.
You will learn how to:
- Achieve efficient, high-purity base editing of therapeutic targets
- Upregulate fetal hemoglobin while preserving cell differentiation
- Multiplexed editing without compromising efficiency or cell growth
- Unlock new possibilities for gene therapy
The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.
Download Resource
A high-fidelity, modular platform for efficient multiplexed engineering of therapeutic hematopoietic stem and progenitor cells.